Three weeks to go until second innovative medicines initiative launch
18.06.14
But aside from the numbers – what does this mean? What will IMI2 really bring to patients? IMI2 is based on the principle of collaborating in an open and inclusive way, with the end goal of delivering tangible benefits to patients. The IMI2 Strategic Research Agenda was specially developed to address areas of unmet medical need, finding inspiration in the World Health Organization’s Priority Medicines Report. Projects envisioned under IMI2 aim to advance trends in personalised medicines; to further R&D in areas of unmet medical need; and to address the regulatory context in hopes of speeding translation from research to innovation. The ultimate aim is getting the right treatment to the right patient, together.
I believe IMI offers a realistic solution to many of the complex issues we are now facing in medicines development. The new sciences have opened opportunities for medical research that no single stakeholder can tackle alone. Therefore IMI2 opens its doors to stakeholders beyond pharma, bringing in other sectors to exploit the potential of these new sciences and technologies.
There is a lot of information on IMI available on the EFPIA website, and I’ve included links to some of my favourite resources below. I hope you will take the time to find out more before July 9 – the day IMI2 will launch and we will see an even bigger life sciences PPP than ever before.
Also keep an eye on EFPIA’s Twitter feed (https://twitter.com/EFPIA) in the coming weeks, as we count down towards the big launch day with IMI stats, facts and figures. You can find info by searching for the hashtag #IMI2 or #JTIs2014.
